Methylprednisolone hemisuccinate
- Generic Name
- Methylprednisolone hemisuccinate
- Brand Names
- Solu-medrol
- Drug Type
- Small Molecule
- Chemical Formula
- C26H34O8
- CAS Number
- 2921-57-5
- Unique Ingredient Identifier
- 5GMR90S4KN
- Background
A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
- Associated Conditions
- Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis
- Associated Therapies
- Palliative Treatment
Effects of Atorvastatin in Graves' Orbitopathy (GO)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- University of Pisa
- Target Recruit Count
- 88
- Registration Number
- NCT03110848
- Locations
- 🇮🇹
Ospedale Cisanello-Endocrinology I and II, Pisa, Italy
A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 115
- Registration Number
- NCT03099122
- Locations
- 🇨🇳
CHINA, China, China
A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy
Phase 4
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- University of Pisa
- Target Recruit Count
- 120
- Registration Number
- NCT03098225
Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Hospital for Special Surgery, New York
- Target Recruit Count
- 86
- Registration Number
- NCT03094663
- Locations
- 🇺🇸
Hospital For Special Surgery, New York, New York, United States
The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis ( SSc )
Early Phase 1
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT03059979
- Locations
- 🇳🇱
Radboudumc, Rheumatology department, Nijmegen, Gelderland, Netherlands
Rituximab Objective Outcome Measures Trial in SLE
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 30
- Registration Number
- NCT03054259
- Locations
- 🇬🇧
Chapel Allerton Hospital- Leeds Institute for Rheumatic and Musculoskeletal Medicine, Leeds, West Yorkshire, United Kingdom
Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2019-05-20
- Target Recruit Count
- 76
- Registration Number
- NCT03018535
- Locations
- 🇮🇹
Division of Nephrology, Montichiari Hospital, ASST Spedali Civili di Brescia, Montichiari, Brescia, Italy
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Phase 3
Active, not recruiting
- Conditions
- Interventions
- Drug: Calaspargase PegolProcedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Dexrazoxane HydrochlorideDrug: DoxorubicinDrug: EtoposideBiological: FilgrastimDrug: IfosfamideDrug: Imatinib MesylateDrug: MethotrexateOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: PegaspargaseDrug: PrednisoloneDrug: MercaptopurineDrug: MethylprednisoloneOther: Questionnaire AdministrationDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 475
- Registration Number
- NCT03007147
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 222
- Registration Number
- NCT02944045
- Locations
- 🇫🇷
Medical ICU, Paris, France
Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2023-02-23
- Target Recruit Count
- 75
- Registration Number
- NCT02921555
- Locations
- 🇪🇸
Hospital Universitario Central de Asturias, Oviedo, Astúrias, Spain
🇪🇸Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, A Coruña, Spain
🇪🇸Hospital de Galdakao, Galdakao, Bilbao, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath